Innate Pharma

France


 
Quantité totale PI 168
Rang # Quantité totale PI 7 663
Note d'activité PI 2,7/5.0    74
Rang # Activité PI 9 533
Symbole boursier
ISIN FR0010331421
Capitalisation 134.5M  (EUR)
Industrie Biotechnology
Secteur Healthcare
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

0 3
51 2
105 2
5
 
Dernier brevet 2024 - Nk cell engager proteins compris...
Premier brevet 2000 - Triggering receptor involved in ...
Dernière marque 2023 - KIRTAMSY
Première marque 2017 - LUMOXITI

Industrie (Classification de Nice)

Derniers inventions, produits et services

2024 Invention Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment...
Invention Modular chimeric antigen receptor. The invention relates to chimeric activating receptor (CAR) si...
Invention Methods for purifying heteromultimeric antibodies. The invention relates to a method of purifying...
2023 Invention Compositions and methods for neoadjuvant treatment in cancer comprising anti-cd39 antibodies. The...
Invention Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering. The pre...
Invention Nectin-4 binding agents. The invention relates to antibodies and antibody fragment that bind to N...
P/S Préparations pharmaceutiques.
P/S Pharmaceutical preparations.
P/S Pharmaceutical preparations for the treatment of cancer, immunoproliferative disorders, inflammat...
2022 Invention Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a. Multisp...
Invention Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2. The present inventi...
Invention Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a. The inv...
Invention Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a. Multisp...
Invention Immunohistochemistry methods and kir3dl2-specific reagents. The present invention relates to anti...
Invention Cytokine anchors for nkp46-binding nk cell engager proteins. Multi-specific proteins that bind to...
Invention Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to...
2021 Invention Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123. The present disclos...
Invention Treatment of cancer. The invention relates to antigen-binding proteins capable of binding to Nect...
P/S Chemical or biotechnological products for industry and science, namely, polypeptides and proteins...
Invention Subcutaneous anti-c5ar antagonist treatment regimen with avdoralimab. The present invention conce...
Invention Cell surface mica and micb detection using antibodies. The present disclosure relates to research...
Invention Cancer treatment methods using anti-cd73 antibodies. The disclosure relates to methods and compos...
Invention Use of cd160 as a biomarker in acute myeloid leukemia. Natural killer (NK) cells are innate cytot...
P/S Chemical or biotechnological products for industry and science, biological preparations, in parti...
Invention Treatment of cancer. The present invention provides antigen-binding proteins capable of binding t...
2020 Invention Treatment of cancer with ilt-2 inhibitors. This invention relates to the use of a NKG2A-neutraliz...
Invention Combination of monalizumab, durvalumab, chemotherapy and bevacizumab or cetuximab for the treatme...
Invention Cd73 blocking antibodies. The present invention relates to antibodies, and fragments thereof, tha...
Invention Treatment of t cell lymphoma. The present invention relates to methods for the treatment of T cel...
2019 Invention Leucocyte immunoglobulin-like receptor neutralizing antibodies. This invention relates to agents ...
Invention Compounds and methods for treatment of head and neck cancer. This invention relates to the use of...
Invention Leucocyte immunoglobulin-like receptor 2 neutralizing antibodies. This invention relates to agent...
Invention Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibo...
Invention Compositions and methods for treating cancer. The present invention relates to antigen-binding co...
Invention Treatment of cancer. The present invention relates to the use of NKG2A-neutralizing agents and PD...
Invention Methods for treating cancer by targeting nidogen-1. This invention relates to methods of treating...
Invention Treatment of head and neck cancer. This invention relates to the use of NKG2A-targeting agents fo...
2018 Invention Multispecific antigen binding proteins. Multimeric multispecific proteins that bind multiple targ...
Invention Potentiating the effect of atp release. The present invention relates to methods of using compoun...
2017 P/S Pharmaceutical preparations and substances.